Biolase Gets FDA Nod for EPIC 10S - Analyst Blog
April 15 2013 - 12:20PM
Zacks
Recently, a pioneer in
manufacturing and distributing dental lasers, BIOLASE,
Inc. (BIOL) obtained regulatory clearance from the U.S.
Food & Drug Administration (FDA) for its EPIC 10S soft tissue
diode laser. Last month the company received FDA approval for
another diode soft tissue laser, Diolase 10 diode soft tissue
laser. EPIC 10S has been approved for surgical use across more than
19 medical markets for more than 80 different indications.
The 19 medical markets include
plastic surgery, oral surgery, orthopedics, dermatology, podiatry,
gynecology, cardiac surgery, urology, thoracic surgery, vascular
surgery, aesthetics, ophthalmology, general surgery, and ear, nose
and throat among others. Additionally, this product is also cleared
by the FDA for temporary pain relief and tooth whitening.
BIOLASE's diode lasers are used as
an alternative to the ideal surgical devices, which are traumatic
and invasive in nature. EPIC 10S, a part of Biolase’s diode lasers,
consumes low power, generates less heat and increases comfort while
surgery. The product operates under 940nm wavelength, under which
chances of infection and contamination are reduced
considerably.
The FDA clearance allows the
company to expand its EPIC 10S platform along with the consumable
business across a wide market of multi-billion dollar medical
products..
BIOLASE develops and markets lasers
and related products for applications in medicine and dentistry.
Its key products, the dental laser systems, perform a broad
spectrum of dental procedures, including cosmetic and complex
surgical applications. To date the company has worked with over 340
patents and patent pending technologies made to deliver efficient
performance with speed, less pain and more efficiency. To date, the
company has sold more than 22,000 lasers.
Currently Biolase carries a Zacks
Rank #3 (Hold). Other medical and laser instrument stocks worth
considering are Cutera, Inc. (CUTR), Given
Imaging Ltd. (GIVN) and Cepheid (CPHD),
all of which carry a Zacks rank #1 (Strong Buy).
BIOLASE TECH (BIOL): Free Stock Analysis Report
CEPHEID INC (CPHD): Free Stock Analysis Report
CUTERA INC (CUTR): Free Stock Analysis Report
GIVEN IMAGING (GIVN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Sep 2023 to Sep 2024